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V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in
a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-
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BACKGROUND
In the previously reported primary analysis of this phase 3 trial, 12 months of 
adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free 
survival than placebo in patients with resected stage III melanoma with BRAF 
V600E or V600K mutations. To confirm the stability of the relapse-free survival 
benefit, longer-term data were needed.
METHODS
We randomly assigned 870 patients who had resected stage III melanoma with 
BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose 
of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. 
The primary end point was relapse-free survival. Here, we report 5-year results for 
relapse-free survival and survival without distant metastasis as the site of the first 
relapse. Overall survival was not analyzed, since the required number of events to 
trigger the final overall survival analysis had not been reached.
RESULTS
The minimum duration of follow-up was 59 months (median patient follow-up, 60 
months for dabrafenib plus trametinib and 58 months for placebo). At 5 years, the 
percentage of patients who were alive without relapse was 52% (95% confidence 
interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 
41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61). The 
percentage of patients who were alive without distant metastasis was 65% (95% 
CI, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI, 49 to 60) with 
placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70). 
No clinically meaningful between-group difference in the incidence or severity of 
serious adverse events was reported during the follow-up period.
CONCLUSIONS
In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III 
melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy 
with dabrafenib plus trametinib resulted in a longer duration of survival without 
relapse or distant metastasis than placebo with no apparent long-term toxic effects. 
(Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, 
NCT01682083; EudraCT number, 2012 - 001266 - 15.)
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F
or patients with high-risk resected 
melanoma, immune checkpoint inhibitors 
and BRAF plus MEK inhibitors (dabrafenib 
plus trametinib) are well-established adjuvant 
therapies. In such patients, the side-effect pro-
file and long-term benefit of the drugs are im-
portant criteria for selecting the appropriate 
therapy.1 Immune checkpoint inhibitors that tar-
get programmed cell death 1 (PD-1) protein 
(nivolumab and pembrolizumab) and the targeted 
therapy combination of dabrafenib plus trameti-
nib have shown significant relapse-free survival 
benefits and are considered to be current stan-
dard-of-care adjuvant therapies. However, the 
durability of these benefits with continued fol-
low-up remains an important open question.
In extended follow-up from phase 3 trials of 
the immune checkpoint inhibitor ipilimumab 
(targeting cytotoxic T-lymphocyte–associated pro-
tein 4),2,3 results in one study showed relapse-
free survival in 39% of the patients and overall 
survival in 60% at 7 years.2 However, ipilimumab 
is no longer considered to be a standard-of-care 
adjuvant therapy after recent advances with anti–
PD-1 and BRAF-targeted therapies.4,5 The primary 
analyses of phase 3 trials of PD-1 inhibitors in 
patients who had melanoma with or without a 
BRAF V600 mutation showed significant relapse-
free survival benefits at 1 year in comparisons 
between pembrolizumab and placebo (75.4% vs. 
61.0%; hazard ratio, 0.57; 98.4% confidence in-
terval [CI], 0.43 to 0.74; P<0.001) in patients with 
resected stage III disease6 and between nivolumab 
and ipilimumab (70.5% vs. 60.8%; hazard ratio, 
0.65; 97.56% CI, 0.51 to 0.83; P<0.001) in patients 
with resected stage IIIB/IIIC/IV disease.7 Long-
term data regarding relapse-free and overall sur-
vival for these agents are not yet available.6-9
In the phase 3 COMBI-AD trial involving pa-
tients with resected stage III melanoma with 
BRAF V600E or V600K mutations, 12 months of 
adjuvant dabrafenib plus trametinib resulted in 
significantly longer 3-year relapse-free survival 
than placebo (58% vs. 39%; hazard ratio, 0.47; 
95% CI, 0.39 to 0.58; P<0.001).10,11 The 3-year 
comparison of overall survival between dab-
rafenib plus trametinib and placebo (86% vs. 
77%; hazard ratio, 0.57; 95% CI, 0.42 to 0.79; 
P = 0.0006) in a preplanned interim analysis that 
was based on a 26% information fraction did not 
reach the prespecified significance threshold of 
P = 0.000019.11
To confirm the long-term stability of the 
relapse-free survival benefit associated with 12 
months of adjuvant dabrafenib plus trametinib, 
here we report the 5-year analyses, including 
relapse-free survival and survival without distant 
metastasis (with distant metastasis as the site of 
first relapse),12 based on extended follow-up 
from the COMBI-AD trial.
Me thods
Trial Design, Patients, and Treatment
COMBI-AD is a randomized, double-blind, pla-
cebo-controlled, phase 3 trial in which enroll-
ment was conducted from January 2013 through 
December 2014 at 169 sites in 25 countries. Pa-
tients were randomly assigned to receive dab-
rafenib at a dose of 150 mg twice daily plus 
trametinib at a dose of 2 mg once daily (combi-
nation therapy) or two matched placebos for 12 
months. Eligible adults (age, ≥18 years) had un-
dergone complete resection of histologically con-
firmed stage IIIA melanoma with lymph-node 
metastasis measuring at least 1 mm, stage IIIB 
melanoma, or stage IIIC melanoma, according 
to the criteria of the seventh edition of the Amer-
ican Joint Committee on Cancer cancer-staging 
manual (AJCC-7). In addition, all the patients had 
positive results for BRAF V600E or V600K muta-
tions, as confirmed in primary tumor or lymph-
node tissue by a central reference laboratory. 
Patients were required to have undergone com-
pletion lymphadenectomy (i.e., without clinical 
or radiographic indication of remaining regional 
nodal disease) within 12 weeks before random-
ization and to have an Eastern Cooperative On-
cology Group performance-status score of 0 or 1 
(on a 5-point scale, with higher numbers reflect-
ing greater disability). Full inclusion and exclu-
sion criteria have been reported previously.11
Patients were stratified according to BRAF 
mutation type (V600E or V600K) and disease 
stage (IIIA, IIIB, or IIIC). Treatment continued 
for 12 months or until disease relapse, unaccept-
able toxic effects, withdrawal of consent, or 
death, whichever occurred first. Patients were 
followed up for disease relapse until the first 
relapse was observed and were then followed for 
survival. After relapse or trial discontinuation, 
subsequent anticancer therapy was permitted at 
the investigator’s discretion, and patients were 
to remain in follow-up for an analysis of sur-
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vival. Unblinding was permitted only if knowl-
edge of the trial treatment was essential for ap-
propriate clinical management or if a serious 
adverse event occurred.
End Points
The primary end point was relapse-free survival, 
which was defined as the time from randomiza-
tion until disease recurrence or death from any 
cause. Secondary end points were overall survival, 
survival without distant metastasis (defined as 
the time from randomization until the date of 
the first distant metastasis or death, whichever 
occurred first),12 freedom from relapse (defined 
as the time from randomization until recur-
rence, with censoring of data for patients who 
had died from causes other than melanoma or 
treatment-related toxic effects), and safety. The 
subgroup analysis of relapse-free survival was 
performed on the basis of disease stage (per 
prevailing AJCC-7 criteria at the time of the trial) 
and was a prespecified analysis to assess the 
homogeneity of treatment effect; assessment ac-
cording to the updated AJCC-8 criteria was per-
formed as a post hoc analysis. (A description of 
these staging criteria is provided in the Methods 
section in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.) All 
the analyses were based on investigator assess-
ment in the intention-to-treat sample (i.e., all the 
patients who had undergone randomization). 
According to the trial protocol (available at 
NEJM.org), patients with a first relapse at a loco-
regional site were not required to continue fol-
low-up for distant metastases, and their data 
were censored for the analysis of survival with-
out distant metastasis at the time of locore-
gional recurrence if follow-up was not complete. 
Because the protocol-specified number of events 
had not yet been reached, no overall survival 
analysis was conducted at the time of the current 
analysis.
Assessments
Imaging with the use of computed tomography, 
magnetic resonance imaging, or both was initial-
ly performed every 3 months; after 24 months, 
assessments continued every 6 months until 
5 years and then every 12 months until relapse 
or trial completion. Dermatologic assessments 
to screen for relapse or cutaneous adverse events 
were performed every 2 months for the 12-month 
duration of treatment, then every 3 months dur-
ing the first 24 months of follow-up; subsequent 
dermatologic evaluations during follow-up con-
tinued every 6 months until 5 years and then 
every 12 months. Adverse events were recorded 
from administration of the first dose of dab-
rafenib plus trametinib or placebo until 30 days 
after discontinuation of the trial treatment. Dose 
modifications and interruptions were permitted 
according to the protocol. After the treatment 
period, reporting of treatment-related adverse 
events was at investigator discretion. Only treat-
ment-related serious adverse events and new 
cancers were required to be reported during 
follow-up.11
Trial Oversight
COMBI-AD was initially sponsored by Glaxo-
SmithKline; dabrafenib and trametinib became 
assets of Novartis on March 2, 2015, after which 
Novartis took over sponsorship of the trial. The 
trial was conducted in accordance with the pro-
visions of the Declaration of Helsinki. The trial 
protocol was approved by the institutional re-
view board or independent ethics committee at 
each trial center and has been published previ-
ously. All the patients provided written informed 
consent before enrollment.
The data were collected by staff members at 
each trial site and monitored by the sponsor and 
independent data and safety monitoring com-
mittees. The sponsor was also involved in the 
analysis and interpretation of the data and in the 
writing of the manuscript. All the authors had 
full access to all trial data. Editorial support was 
provided by ArticulateScience and funded by 
Novartis.
Statistical Analysis
We determined that the enrollment of 870 pa-
tients would result in disease relapse or death in 
approximately 410 patients by the time of the 
primary analysis (with a two-sided type I error 
rate of 5%) and would provide a power of more 
than 90% to detect a hazard ratio of 0.71.
We estimated the duration of survival both 
without relapse and without distant metastasis 
using the Kaplan–Meier method and calculated 
hazard ratios and 95% confidence intervals us-
ing the Pike estimator.13,14 The data for most pa-
tients who had a first relapse at a locoregional 
site were censored for the analysis of survival 
n engl j med nejm.org 4
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without distant metastasis at the time of locore-
gional recurrence.12 No formal claims of statisti-
cal significance have been made, so no adjust-
ments for multiple comparisons were performed.
R esult s
Patients
In the COMBI-AD trial, a total of 870 patients 
underwent randomization (438 to receive dabra-
fenib plus trametinib and 432 to receive place-
bo). The characteristics of the patients were well 
balanced at baseline in the two trial groups 
(Table S1 in the Supplementary Appendix).10,11 
All the patients had completed treatment at the 
time of this 5-year analysis; the last patient re-
ceived the final dose of dabrafenib plus tra-
metinib or placebo in December 2015. The full 
12 months of administration of dabrafenib, 
trametinib, or placebo was completed by 63%, 
64%, and 53% of the patients, respectively. The 
median daily doses of dabrafenib (284 mg) and 
trametinib (2 mg) were similar to the planned 
daily doses.11 At the time of the data cutoff 
(November 8, 2019), 278 patients (63%) in the 
combination-therapy group and 234 (54%) in the 
placebo group remained in follow-up (Fig. S1 and 
Table S2). The minimum duration of follow-up 
was 59 months, and the median patient follow-
up was 60 months in the combination-therapy 
group and 58 months in the placebo group.
Relapse-free Survival
At the data cutoff for the 5-year analysis, disease 
relapse or death before documented relapse had 
occurred in 190 of 438 patients (43%) in the 
combination-therapy group and in 262 of 432 
(61%) in the placebo group. The median relapse-
free survival was not reached (NR) in the com-
bination-therapy group (95% CI, 47.9 to NR) and 
was 16.6 months (95% CI, 12.7 to 22.1) in the 
placebo group (hazard ratio for relapse or death, 
0.51; 95% CI, 0.42 to 0.61). At 5 years, the per-
centage of patients who were alive without re-
lapse was 52% (95% CI, 48 to 58) in the combi-
nation-therapy group and 36% (95% CI, 32 to 41) 
in the placebo group, as compared with percent-
ages of 55% (95% CI, 50 to 60) and 38% (95% 
CI, 34 to 43), respectively, at 4 years (Fig. 1A). 
Hazard ratios for relapse-free survival favored 
dabrafenib plus trametinib across all patient 
subgroups that were evaluated (Fig. 1B). Among 
patients who had a relapse, a first relapse at a 
distant site was more common than at a loco-
regional site in the two groups (Table S3).
Relapse-free Survival, According to Disease 
Stage
In the 5-year analysis, the duration of relapse-
free survival was longer with dabrafenib plus 
trametinib than with placebo across all stage III 
substages on the basis of Kaplan–Meier analysis 
of survival data, according to AJCC-7 criteria. 
Among the patients with stage IIIA disease, the 
percentage of patients who were alive without 
relapse was 65% (95% CI, 55 to 77) with dab-
rafenib plus trametinib and 58% (95% CI, 46 to 
72) with placebo (hazard ratio for relapse or 
death, 0.61; 95% CI, 0.35 to 1.07). In those with 
stage IIIB disease, the percentage was 55% (95% 
CI, 47 to 63) and 34% (95% CI, 28 to 42), respec-
tively, with a hazard ratio of 0.50 (95% CI, 0.37 
to 0.67). In patients with stage IIIC disease, the 
percentage was 45% (95% CI, 38 to 53) and 29% 
(95% CI, 23 to 37), respectively, with a hazard 
ratio of 0.48 (95% CI, 0.36 to 0.64) (Fig. 2). Post 
hoc analysis of relapse-free survival according to 
the revised AJCC-8 criteria showed a similar 
benefit with dabrafenib plus trametinib versus 
placebo across stage IIIA, IIIB, IIIC, and IIID 
disease (Fig. S2).
Survival without Distant Metastasis
At the cutoff for this analysis, a distant relapse 
or death before documentation of distant metas-
tasis had occurred in 126 of 438 patients (29%) 
in the combination-therapy group and in 159 of 
432 (37%) in the placebo group. The data for 
most patients who had a first relapse at a locore-
gional site were censored for distant relapse at 
the time of locoregional recurrence because 
follow-up for distant metastasis was not man-
dated by the protocol in such patients. Survival 
without distant metastasis favored dabrafenib 
plus trametinib over placebo with extended fol-
Figure 1 (facing page). Relapse-free Survival.
Shown are Kaplan–Meier estimates of relapse-free sur-
vival in the intention-to-treat population (Panel A) and 
a forest plot of hazard ratios for relapse or death in 
subgroups of patients (Panel B). The hatch marks in 
Panel A indicate censoring of data. AJCC-7 denotes the 
seventh edition of the American Joint Committee on 
Cancer cancer-staging manual, and NR not reached.
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low-up. At 5 years, the percentage of patients 
who were alive without distant metastasis was 
65% (95% CI, 61 to 71) in the combination-
therapy group and 54% (95% CI, 49 to 60) in the 
placebo group (hazard ratio for distant metasta-
sis or death, 0.55; 95% CI, 0.44 to 0.70) (Fig. 3). 
An analysis of survival without distant metasta-
sis according to the disease stage at baseline 
(AJCC-7 criteria) showed similar treatment ben-
efit favoring dabrafenib plus trametinib over 
placebo, regardless of the disease stage (Fig. S3).
Safety
The last patient received the last dose of dab-
rafenib plus trametinib or placebo in December 
2015. There was no clinically meaningful differ-
ence between the combination-therapy group 
and the placebo group in the incidence or sever-
ity of serious adverse events reported during the 
follow-up period.
Subsequent Therapy
A total of 173 of 435 patients (40%) in the 
combination-therapy group and 232 of 432 (54%) 
in the placebo group received subsequent thera-
py. The median interval between disease recur-
rence and subsequent therapy (excluding surgery 
and radiotherapy) was 7.9 weeks in the two trial 
groups. The most common subsequent systemic 
anticancer therapy was immunotherapy in the 
combination-therapy group (114 patients [26%]) 
and small-molecule targeted therapy in the pla-
cebo group (153 patients [35%]) (Table 1).
Discussion
In this 5-year analysis, we found that 12 months 
of adjuvant treatment with dabrafenib plus tra-
metinib conferred a durable long-term, relapse-
free survival benefit for patients with resected 
Figure 2 (facing page). Relapse-free Survival, According to 
Stage III Substage.
Shown are Kaplan–Meier estimates of relapse-free sur-
vival in patients in the intention-to-treat population with 
melanoma of stage IIIA (Panel A), stage IIIB (Panel B), 
or stage IIIC (Panel C), according to the AJCC-7 criteria.
Figure 3. Survival without Distant Metastasis.
Shown are Kaplan–Meier estimates of survival without distant metastasis in the intention-to-treat population. This analysis includes 
 patients with a distant metastasis as the site of first relapse. According to the protocol, in patients with a first relapse at a locoregional 
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stage III melanoma with BRAF V600E or V600K 
mutations, a benefit that persisted several years 
after the end of treatment. The tails of the 
 Kaplan–Meier curves for relapse-free survival in 
the two groups showed evidence of stabilization, 
with a decrease in the number of events over 
time. This finding suggests that the percentage 
of patients who remained relapse-free long-term 
after surgery was higher among those who re-
ceived dabrafenib plus trametinib than among 
those who underwent surgery alone. Longer 
follow-up is necessary to assess whether this 
lower incidence of disease recurrence will lead to 
a longer duration of overall survival.
The decreasing incidence of disease recurrence 
or death over time suggests that the Kaplan–
Meier curves are reaching a plateau. In patients 
treated with dabrafenib plus trametinib, the es-
timated percentage of patients who were alive 
without relapse was 55% at 4 years and 52% at 
5 years. Furthermore, between the time that the 
primary analysis was performed (median follow-
up, 34 months)11 and the time of the current 
analysis (median follow-up, 60 months), relapses 
or deaths were reported in an additional 24 pa-
tients in the combination-therapy group and 
in an additional 14 in the placebo group. The 
between-group difference in the number of events 
was due to the difference in the number of pa-
tients at risk during the follow-up period. Previ-
ous studies have suggested that the majority of 
relapses in patients with resected stage III dis-
ease occur within the initial 3 years after sur-
gery,15 which is consistent with the observations 
in the two groups in our trial. Taken together, 
these results suggest that treatment with dab-
rafenib plus trametinib does not merely delay 
relapse but increases the percentage of patients 
who are likely to remain relapse-free in the long 
term. Ongoing trials of anti–PD-1 therapies that 
enrolled patients with or without BRAF V600-
mutated disease may show similar evidence of 
long-term relapse-free survival benefit. Such re-
sults are not yet available, since the latest data 
from the CheckMate 238 and KEYNOTE-054 
trials were reported for 3-year analyses.8,9
Completion lymphadenectomy was part of the 
inclusion criteria for all three pivotal trials of 
current standard-of-care adjuvant therapies.6,7,11 
However, based on the results of the Multicenter 
Selective Lymphadenectomy Trial II (MSLT-II) and 
the German Dermatologic Cooperative Oncology 
Group (DeCOG) trial, relevant guidelines have 
been amended and no longer require completion 
lymphadenectomy in most patients with stage III 
disease.4,5,16,17 We are not aware of any data sug-
gesting differential benefit for any standard-of-
care adjuvant systemic therapy in patients with 
or without completion lymphadenectomy.
Durable survival without distant metastasis 
favoring the combination-therapy group was 
also observed with extended follow-up, with the 
two groups showing a plateau at the tail of the 
Kaplan–Meier curves. Since the time of the pri-
mary analysis,11 distant relapse or death before 
documentation of distant metastasis was report-
ed in 16 patients who received dabrafenib plus 
trametinib and in 7 who received placebo. The 
analysis involving patients who survived without 
distant metastasis included those who had a dis-
tant metastasis as their first site of relapse; most 
patients with a first locoregional relapse were 
not followed for the occurrence of distant metas-
tasis. Although the informative censoring in this 
trial deviates somewhat from the intention-to-
treat principle, it is likely to favor the placebo 
group, which had a higher number of patients 
with a first relapse at a locoregional site than 
did the combination-therapy group.12 Therefore, 







no. of patients (%)
Any anticancer therapy† 173 (40) 232 (54)
Systemic anticancer therapy
Any therapy 148 (34) 202 (47)
Chemotherapy 23 (5) 30 (7)
Immunotherapy 114 (26) 120 (28)
Anti–PD-1 97 (22) 90 (21)
Anti–CTLA-4 71 (16) 80 (19)
Biologic therapy 8 (2) 13 (3)
Small-molecule targeted therapy 85 (20) 153 (35)
*  Patients could have undergone more than one subsequent systemic anticancer 
therapy. CTLA-4 denotes cytotoxic T-lymphocyte–associated protein 4, and 
PD-1 programmed cell death 1.
†  Anticancer therapies other than systemic therapy included surgery and radio-
therapy.
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the benefit in the combination-therapy group for 
survival without distant metastasis may be un-
derestimated.
At the time of the earlier reported interim 
analysis that was based on an information frac-
tion of 26%, overall survival results favored com-
bination therapy with dabrafenib plus trametinib 
over placebo, but the prespecified interim signifi-
cance threshold of P = 0.000019 was not met.11 At 
the current data cutoff, a total of 216 deaths 
were reported in the two trial groups, and the 
per-protocol number of events (approximately 299) 
to trigger the final overall survival analysis had 
not been reached. In the absence of long-term 
overall survival data, the Weibull mixture model 
for cure rate estimation provides a method to 
assess long-term outcomes through estimation 
of the percentage of patients who may not have 
a relapse. Notably, overall survival in our trial 
may be affected by the 47% of patients who re-
ceived subsequent anticancer therapy; a strength 
of cure rate modeling is that it is based on relapse-
free survival and thus not influenced by subse-
quent therapies. However, it does rely on the 
assumption that a subgroup of patients will be 
cured, which cannot be empirically tested. Esti-
mated cure fractions that are based on the previ-
ous data cutoff (on April 30, 2018) were 54% 
(95% CI, 49 to 59) in the combination-therapy 
group and 37% (95% CI, 32 to 42) in the placebo 
group.10 The current analyses provide further 
support for these long-term survival benefits as 
we await the final overall survival analysis.
Updated safety analyses were not performed 
at this data cutoff because no patients were con-
tinuing to receive therapy during the extended 
follow-up period, and reporting of treatment-
related adverse events after that point was at the 
investigator’s discretion. The vast majority of pa-
tients had treatment-related adverse events only 
during the initial 12-month treatment window. 
Nearly all the adverse events that were associated 
with dabrafenib plus trametinib were transient 
and resolved after the discontinuation or inter-
ruption of treatment, as expected on the basis of 
the mechanisms of action and pharmacokinetic 
measurements of these agents.18,19 Both the bene-
fits and risks of treatment should be taken into 
consideration and discussed with patients for 
informed decision making regarding therapy.
Overall, this 5-year analysis featuring extended 
follow-up from the phase 3 COMBI-AD trial 
confirms that 12 months of adjuvant therapy 
with dabrafenib plus trametinib led to durable 
long-term benefit regarding relapse-free survival 
in patients with resected stage III melanoma with 
BRAF V600 mutations. The effect of adjuvant 
therapy with dabrafenib plus trametinib on long-
term overall survival remains to be determined.
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